NeurAxis Announces CareFirst BCBS Policy Coverage
2023年11月15日 - 11:00PM
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:
NRXS), a medical technology company commercializing neuromodulation
therapies addressing chronic and debilitating conditions in
children and adults, today announced receipt of CareFirst Blue
Cross Blue Shield (“CareFirst BCBS”) policy coverage for the
mid-Atlantic region with 3.5 million lives. CareFirst BCBS is the
largest healthcare insurer in the mid-Atlantic that includes
Maryland, Washington DC, and Northern Virginia.
“We are pleased to announce new policy coverage
from CareFirst BCBS, which is in line with our strategy to leverage
clinical evidence supporting IB-Stim™ to obtain payer coverage and
then drive market adoption of our technology,” said Brian Carrico,
President and Chief Executive Officer of NeurAxis. “With CareFirst
BCBS, our covered lives now stands at 8.25 million and we look
forward to receiving positive response from payers on a national
level as we close in on all data being published.”
About NeurAxis, Inc.NeurAxis,
Inc., is a medical technology company focused on neuromodulation
therapies to address chronic and debilitating conditions in
children and adults. NeurAxis is dedicated to advancing science and
leveraging evidence-based medicine to drive the adoption of its
IB-Stim™ therapy, which is its proprietary Percutaneous Electrical
Nerve Field Stimulation (PENFS) technology, by the medical,
scientific, and patient communities. IB-Stim™ is FDA-cleared for
functional abdominal pain associated with irritable bowel syndrome
(IBS) in adolescents 11-18 years old. Additional clinical trials of
PENFS in multiple pediatric and adult conditions with large unmet
healthcare needs are underway. For more information, please visit
http://neuraxis.com/.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. There are a number of important factors
that could cause actual results, developments, business decisions
or other events to differ materially from those contemplated by the
forward-looking statements in this press release. These factors
include, among other things, the conditions in the U.S. and global
economy, the trading price and volatility of the Company’s stock,
public health issues or other events, the Company’s compliance with
applicable laws, the results of the Company’s clinical trials and
perceptions thereof, the results of submissions to the FDA, the
results of the shareholder vote to enable the issuance of the
Preferred Stock, and factors described in the Risk Factors section
of NeurAxis’s public filings with the Securities and Exchange
Commission (SEC). Because forward-looking statements are inherently
subject to risks and uncertainties, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements speak only as of the date of this press
release and, except to the extent required by applicable law, the
Company undertakes no obligation to update or revise these
statements, whether as a result of any new information, future
events and developments or otherwise.
Contacts:
CompanyNeurAxis,
Inc.info@neuraxis.com
Investor
RelationsGilmartin
GroupIR@neuraxis.com
Neuraxis (AMEX:NRXS)
過去 株価チャート
から 8 2024 まで 9 2024
Neuraxis (AMEX:NRXS)
過去 株価チャート
から 9 2023 まで 9 2024